GLSI
Greenwich LifeSciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.95
+2.05%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.4x
Market Cap
$234.12M
MomentumView details →
1D Return
+2.05%
YTD Return
−24.13%
RSI (14)
47.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.4x
Market Cap
$234.12M
RSI (14)
47.7
MomentumView details →
1D Return
+2.05%
YTD Return
−24.13%
SummaryUpdated Jun 1, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Stafford, Texas. Originally incorporated as Norwell, Inc., the company changed its name to Greenwich LifeSciences in March 2018 and went public in September 2020. The company focuses exclusively on developing novel cancer immunotherapies targeting breast cancer and other cancers that express the HER2/neu protein, with its lead product candidate GP2 having completed Phase IIb clinical trials.
Similar companies
Latest newsMore news →
Greenwich LifeSciences' Board of Directors extended the lock-up of shares held by its directors, officers, and pre-IPO investors to January 31, 2027, restricting their sale of common stock until that date.25d agoGreenwich LifeSciences received regulatory approval to expand its Phase III clinical trial FLAMINGO-01 into the United Kingdom.44d ago